Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Concord Biotech's formulation facility clears regulatory inspections by Kenya's PPB & Uganda's NDA
Concord Biotech has announced the successful completion of inspection of the company's Unit-II formulation facility by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda.
Stock Picks Today: SBI, HDFC AMC, Nestle, Hero Moto, Kajaria, Syngene, Concord Biotech, And More On Brokerages' Radar
Brokerages' Radar
Concord Biotech completes ANVISA inspection at Limbasi API facility
Concord Biotech announced the successful completion of an inspection conducted by Brazil's National Health Surveillance Agency (ANVISA) at its active pharmaceutical ingredient (API) manufacturing facility in Limbasi.
Concord Biotech, Carysil among top stocks to buy today; check targets
Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Concord Biotech, Carysil, and Welspun Enterprises today
Wipro Buyback Starts Today | Concord Biotech Gets USFDA Nod | Top Buzzing Stocks Today - Equitymaster
Wipro Buyback Starts Today | Concord Biotech Gets USFDA Nod | Top Buzzing Stocks TodayEquitymaster
Wipro Buyback Starts Today | Concord Biotech Gets USFDA Nod | Top Buzzing Stocks Today - Equitymaster
Wipro Buyback Starts Today | Concord Biotech Gets USFDA Nod | Top Buzzing Stocks TodayEquitymaster
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.
Concord Biotech receives USFDA approval for Tofacitinib Tablets
Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA).
Concord Biotech share rises 6% after USFDA clears Tofacitinib Tablets ANDA
Concord Biotech shares jumped 5.8 per cent on BSE after USFDA cleared Tofacitinib Tablets ANDA
Concord Biotech shares gain 5% after bagging USFDA approval for $500 million drug
According to Concord Biotech, this development aligns directly with its long-term growth strategy, aimed at reinforcing its commercial footprint across both US and international markets.
Concord Biotech rallies after USFDA approval for Tofacitinib tablets
Concord Biotech rose 5.38% to Rs 1,340 after the company announced that it has received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths.
Why Is Concord Biotech Stock Up by 8% Today? By Trade Brains - Investing.com India
Why Is Concord Biotech Stock Up by 8% Today? By Trade BrainsInvesting.com India